List of Vendor Companies in Israel - 47

3NT Medical is taking ENT endoscopy further, with a family of novel maneuverable, single-use endoscopes purpose-built for the unique needs of ENT specialists.

Valuing Life, Granting Advanced Therapies to Patients- that Is Adva Biotechnology’s Vision and goal. Adva Biotechnology developed the ADVA-X3- a simple, smart, easy to use, automated, sensors-based, flexible cell manufacturing platform. The ADVA-X3 enables full manufacturing process based on the CAMP™ technology, of different applications, such as CAR-T, TCR, TIL, NK, Exosomes, Viruses and More.

Aleph Farms®, an Israel-based cellular agriculture company, enhances sustainability, food security and animal welfare by diversifying the supply and decentralizing the production of quality animal proteins and fats as a complement to sustainable methods of conventional animal agriculture. Founded in 2017, the company unveiled the world's first cultivated thin-cut beef steak in 2018, the world's first cultivated ribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts™, the company is launching its first product, the cultivated Petit Steak, grown from non-modified cells of a premium Black Angus cow. For its contributions to climate leadership, including a net zero commitment made in 2020, it has received top accolades from the World Economic Forum and the United Nations.

Amai develops novel proteins that answer the needs of consumers and industry. The first application is sweet protein, inspired by nature, and built with biology through a natural fermentation process. With its pro-protein platform, the company creates new breakthroughs which are set to shape the future of proteins.

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) is a public biotech company that has developed a patented Botanical Synthesis platform technology capable of growing the active and beneficial compounds in fruit & plants, at an industrial scale, without the need to grow the plant itself. BioHarvest has invested 16 years and >$75M to develop our Botanical Synthesis Technology, which produces unique and patentable botanical compositions which contain a "target optimized" combination of the phyto-medicinal compounds (with high solubility and bio-availability) found in the original plant. No other company has developed a commercially viable plant cell culture platform at the industrial scale of BioHarvest. BioHarvest is focused on leveraging this platform technology across the following business units: 1. Plant Cell Culture Development and Manufacturing: BioHarvest is leveraging its Botanical Synthesis technology to allow global pharmaceutical, cosmeceutical, and nutraceutical partners to develop proprietary botanical formulations with unmatched predictability and consistency, manufactured at industrial scale under exclusive partnerships. 2. Direct to Consumer/Direct to Doctor Nutraceuticals Business Anchored in Science: BioHarvest has built its own direct to consumer business of propriety botanical compositions. The first product, VINIA® was launched into the US in 2021 and has exceeded 50,000 users (>$20M USD Revenue). VINIA® contains multiple polyphenols, including Piceid Resveratrol, with an amount in each daily 400mg capsule that is equivalent to 1,000 grapes, resulting in a powerful nutraceutical that has been clinically proven (in a published double-blind placebo-controlled study), to significantly increase dilation of arteries. This increased dilation of arteries improves blood flow and the delivery of oxygen and nutrients to the body, tissue & organs. BioHarvest is the only company that produces red grape sourced Piceid resveratrol at an industrial scale

Biology is at a tipping point for implementing AI - thanks to rich data, tool availability, compute capacity, and measurable business impact. Our goal is to empower every scientist and biotech firm, making AI-powered insights a natural part of every workflow. From alt-protein foods to new biopharmaceuticals, bioraptor will make it easier, quicker and more cost-effective for scientists to discover, develop and scale processes that get much-needed food and pharma products into the hands of those who need them.

BlueWind Medical is a medical device company that aims to transform Neurostimulation therapy. Founded in 2010 by the Rainbow Medical Group, BlueWind Medical has successfully completed several clinical studies and is focused on bringing this breakthroughRENOVA™ neuromodulation device for the treatment of Overactive Bladder to the market.

BrainsGate is a medical device company committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases. The company's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on two directions: treatment of acute ischemic stroke, and chronic SPG stimulation to treat vascular dementia patients.

For the first time, researchers and companies can accelerate innovation with accessible, accurate, real-time, and reliable Brain Data™ and Brain Insights™.

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect precancerous polyps and enable early intervention and cancer prevention. The Company's disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption. Please view our notice Terms of Use here: https://check-cap.com/terms-of-use/

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.

Converge Bio is at the forefront of integrating Generative AI with biological data. Our mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages.

Convergent R.N.R (CRNR) developed a transformational AI driven robotic radiation platform that was exclusively designed to significantly reduce non-therapeutic dose to adjacent critical structures, disrupting a stagnant radiation therapy/surgery equipment market. The uniquely converging low energy x-ray beam fulfils the un-met proton beam therapy promise, for a less toxic (to nearby organs) radiation solution, at a fraction of the cost, while reducing total cost of ownership by eliminating the need for a concrete bunker.

CytoReason is a tech company transforming biopharma’s decision-making from trial and error to data-driven using an AI Platform of computational disease models. With its extensive database of public and proprietary data, the company maps human diseases – tissue by tissue and cell by cell. Researchers of all levels rely on CytoReason’s technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios.

DermaDetect is an AI driven software which enables remote diagnosis and treatment of skin disorders. Based on the latest technology, the system helps health care providers grow the efficiency of their workflow, profitability of their clinic while significantly improving patient care. Based on intelligent software, the platform integrates easily with existing systems, is easy to use, accessible 24/7 and has an attractive pay-per usage pricing model.

Founded in 2014, our company pioneered the first artificial pancreas technology. Since then, DreaMed has dedicated itself to developing decision-support tools in the diabetes management field. We are the world's first and only company to receive FDA clearance for a decision support system that utilizes data from CGM/SMBG (continuous glucose monitoring/self-monitoring of blood glucose) and insulin pumps. Our founders are all physicians and engineers. Our products are developed based on real insights from the clinical practice of diabetes specialists, physicians, and clinical researchers from the top diabetes centers worldwide. We prioritize privacy, security, quality, and regulatory compliance, operating under a stringent quality management system and adhering to ISO 27001, GDPR, and HIPAA standards. Additionally, our product FDA-cleared.

Eitan Medical is reimagining drug delivery with reliable innovation that puts patients at the center of care, making infusion easier and safer than ever before. Patient safety and care is only the starting point, as Eitan Medical goes beyond, delivering connected, intuitive infusion solutions that are designed to improve patients' and clinicians' quality of life across the continuum of care, including hospital, ambulatory care, and home care solutions. For over a decade, Eitan Medical and its global partners have provided safe, intuitive, and flexible infusion solutions that meet evolving drug delivery needs.

The NEXUS® Aortic Arch Stent Graft System by Endospan is the only CE-approved off-the-shelf branched endovascular aortic arch system. Indicated for wide range of aortic pathologies, including arch aneurysms, thoracic dissections, and PAU, NEXUS® is designed to overcome the specific challenges of the aortic arch anatomy. The NEXUS® "Dock and Lock" modular system provides stable and secured anatomical anchoring and atraumatic sealing in a wide range of anatomies. Privately held Endospan, headquartered in Herzlia (Tel Aviv), Israel, is a pioneer in the endovascular repair of aortic arch disease including aneurysms and dissections. Endospan's NEXUS® Aortic Arch Stent Graft System is the first endovascular off-the-shelf system with CE Mark to treat a greatly underserved group of patients diagnosed with a dilative lesion in, or near the aortic arch. While minimally invasive endovascular repair has been the standard of care for Abdominal Aortic Aneurysm (AAA), Aortic Arch Disease patients with aneurysms or dissections have not been as fortunate and have had little choice but to undergo open-chest surgery with its invasiveness and risks, lengthy hospitalization periods, and prolonged recuperation. For additional information about Endospan, visit their website at www.endospan.com.

Enzymit is setting a new paradigm for bioproduction through the design and creation of novel enzymes that streamline production processes, reduce costs and promote sustainability. Through cell-free, synthetic biology bioproduction, we aim to make faster, simpler, and more cost-effective than fermentation-based methods, meeting the demands of a constantly evolving world. Established in 2020 by experts in computational science, Enzymit uses deep learning algorithms and high-throughput testing methods to develop novel enzymes for various applications such as fine chemical manufacturing, foodtech, health, biodefense and more. Our team collaborates with global manufacturers across multiple industries, driving both expansion and market impact.

Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit: www.evogene.com

HT BioImaging is a medical imaging company based in Tel Aviv, Israel, founded in 2015. The company specializes in innovative imaging technologies aimed at early cancer detection. Its main product is a patented medical imaging platform that uses Heat Diffusion Imaging (HDI) technology to create real-time images from heat diffusion in tissues. This platform is designed for immediate cancer detection at the point of care and in operating rooms. In addition to its primary focus on human healthcare, HT BioImaging has a subsidiary called HTVet, which applies its technology to the veterinary market. HTVet offers HT Vista, a non-invasive medical device that helps veterinarians rule out cancer in pets during clinical visits. The company serves hospitals and clinics, particularly in oncology and surgery, and is supported by a team of experts in various fields, including AI and thermodynamics.

By taking a simple blood test from the mother-to-be, we can read the fetal DNA! No more risky, complicated and late invasive tests like amniocentesis - we are revolutionizing the way prenatal testing is done.

IR-MED Inc. is developing a cutting-edge infrared spectroscopy and AI analysis technology platform as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. Bioinformation is then analyzed using the company's AI process to provide healthcare professionals with decision support in the detection and monitoring of various disease conditions. PressureSafe, the company's first product based on this platform, is a handheld device designed to revolutionize early detection of pressure injuries (PI) affecting skin and underlying tissue. Pressure Injury in the US alone accounts for $26.8B in healthcare spending and results in 60,000 deaths annually. PressureSafe is expected to contributes to early detection of pressure injuries, regardless of patient skin tone. This will drive equitable healthcare and help reduce the toll and cost of PI. IR-MED holds patents protecting its innovation in noninvasive tissue analysis, and in modeling and analysis of subcutaneous tissue.

Isotopia is a global leader in innovative radiopharmaceuticals, driving advancements in medical diagnostics and therapeutic solutions. We specialize in developing, producing, and distributing radiopharmaceutical technologies that transform patient care and support medical research globally. Our Comprehensive Radiopharmaceutical Portfolio: Theranostics products: • Lu-177 chloride (non-carrier added and carrier added) Diagnostic and Imaging products: • Isoportrace®- PSMA-11 kit for Ga-68 labeling for prostate cancer imaging Nuclear Pharmacy products: • PET and SPECT products. Global Operations: 1. Israel: • HEADQUARTERS & LU-177 PRODUCTION SITE: Our global headquarters we are dedicated to the production of Lutetium-177 (Lu-177), a critical radionuclide for cancer therapies. This site ensures consistent quality and supply for our global customer base. • ASEPTIC PLANT & CMO SERVICES: Our aseptic plant in Israel specializes in the production of cold kits and offers comprehensive Contract Manufacturing Organization (CMO) services, including the manufacture of sterile and lyophilized products for clinical trials and commercial applications. 2. Austria: GMP-COMPLIANT LU-177 PRODUCTION: Our Austrian facility adheres to Good Manufacturing Practice (GMP) standards, ensuring high-quality production of Lu-177 for therapeutic use, particularly in cancer treatment. 3. United States: LU-177 ISOTOPIA PRODUCTION: Supporting North American operations, this site is focused on producing FDA-compliant Lu-177 Isotopia, meeting the needs of our customers across the region. Our Mission: Isotopia is dedicated to advancing medical breakthroughs with high-quality radiopharmaceuticals that enhance diagnostic accuracy and therapeutic outcomes worldwide. With over 160 professionals and 3 production sites, including 2 in Israel, we ensure a reliable, compliant supply of radiopharmaceuticals globally.

Limaca Medical Ltd, is a privately held company dedicated to improving endoscopic biopsy results for patients facing potentially life-threatening gastroenterology and pulmonary cancers. Limaca's experienced team of engineers, clinicians, and business professionals have track records of innovating, developing, and commercializing specialized medical devices. Limaca Medical was founded in 2017 in cooperation with Rambam Health Care, a leading Israeli medical center, and The Trendlines Group in collaboration with the Israel Innovation Authority.

Company Profile: LipoCure is start-up that focuses on development of nano-drugs based on liposomes. LipoCure utilizes the vast experience gained by Professor Yechezkel Barenholz, one of the major inventors and developers of the first FDA-approved nano-drug, Doxil®. Doxil is an anti-cancer drug considered as one of the gold standards of nano-drug delivery systems (DDS). The technological and biological knowledge gained during Doxil development has led to the development of anti-cancer nano-drugs with improved efficacy and reduced toxicity compared to Doxil, as well as to the development of anti-inflammatory nano-drugs. The LipoCure pipeline includes 3 projects close to clinical trials and other projects in pre-clinical stages. All the drugs developed by LipoCure share the principles of better control over pharmacokinetics and bio-distribution, passive targeting at the disease site and controlled drug release. All active pharmaceuticals used are generic. The overall superiority of LipoCure's novel drugs stems from the above advantages, enabling achieving an improved therapeutic index by improving efficacy and reducing toxicity. Technology Description: Utilizing the group's expertise in liposomes and nanotechnology, LipoCure has developed a pipeline of products: LC100 – Liposomal doxorubicin nano-drug with greater efficacy and reduced side effects, in particular, reduced hand and foot syndrome in comparison to current pegylated liposomal doxorubicin. LC200 – Long-circulating inflammation-targeted steroidal nano-liposomal drug with improved efficacy profile in pre-clinical animal models to be used as anti-inflammatory and anti-cancer drug. LC400 – ULALA (Ultra-Long-Acting Local Anesthetic) large multi-vesicular liposome hydrogel loaded with bupivacaine, with slow release and improved safety and efficacy demonstrated in first-in-human clinical study phase I.

Lumenis creates and commercializes innovative energy-based technologies that enable a variety of skin, body, and eye care treatments. We have successfully introduced solutions for previously untreatable conditions and designed advanced technologies that have revolutionized existing treatment methods. We are BeautyTech pioneers, empowering people by broadening the horizons of health and celebrating beauty that matters. Lumenis has a rich history of defying technological boundaries, redefining standards within our domains, and transforming people's lives - both inside and out. Our drive for innovation stems from an uncompromising commitment to providing best-in-class technologies and solutions designed to achieve excellent results. Lumenis has a solid global footprint in developed and emerging markets and sales in over 100 countries. Headquartered in Israel and with offices on four continents, our team consists of nearly 1,500 professionals worldwide.

Lydus Medical is a start-up company in the field of Microsurgery developing a novel system for automating the creation of a safe, simple and fast anastomosis. Vesseal™ is an automated microvascular suturing device delivering thread only standardized omni-vessel anastomoses, to enable simple, fast, easy, safe and effective procedures.

MetaSight Diagnostics, a health technology company, is on a mission to create affordable and precise liquid biopsy diagnostics for early detection of a variety of chronic and acute diseases, utilizing proprietary, cost-effective mass spectrometry technologies (metabolomics, lipidomics and proteomics). The company has created the world’s largest and most comprehensive serum metabolomics dataset linked with Electronic Health Records and is pursuing additional omics. This unprecedented platform is used by MetaSight’s team of experts in analytical chemistry, AI, and medicine to develop and commercialize diagnostic products to improve human health.

An internationally-recognized and multi-disciplinary applied research institute, MIGAL specializes in biotechnology and computational sciences, plant science, precision agriculture and environmental sciences as well as food, nutrition and health.

MNDL Bio is a Synthetic Biology startup aiming to reduce cost and production time of food and biotech applications through advanced computational platforms that optimize gene expression. Proud winner of the "Coller Startup Competition" for Edition 2023.

Momentis Surgical (formerly Memic Innovative Surgery) is a medical device company founded in 2013 and based in Tel Aviv, Israel with a wholly owned subsidiary based in Fort Lauderdale, Florida. Momentis is dedicated to transforming the field of robotic surgery by developing innovative small footprint, cost-effective, robotic-assisted technologies and techniques for a growing number of clinical applications. Our goal is to empower surgeons to perform minimally invasive, complex procedures, enabling better patient outcomes, lowering cost of care, and opening access to more surgeons, patients, hospitals, and surgery centers across the globe. Community Guidelines: https://www.momentissurgical.com/social-media-guidelines/

Nanox AI is lighting up new pathways for smart population healthcare management with AI-based solutions, identifying patients at risk of having chronic disease and enabling the start of preventative care pathways. Integrated delivery networks and payers benefit from this technology with more accurate risk-adjustment, timely intervention, and improved quality of health services, while significantly reducing the associated costs. Nanox AI enables better, fairly reimbursed population health management and wellbeing for larger patient populations. #population health #AI #machine learning #digitalhealth #medicalimaging

NeuroKaire is a precision psychiatry and neurology company using a cutting-edge combination of stem-cell technology, genomics, and AI for treatment optimization and effective drug development. NeuroKaire uses this innovative technology to predict the best drug treatment for each patient, enabling faster treatment, fewer side effects, and lower dosing.

Oxitone is a leading wearables and digital health company helping providers deliver continuous remote care for people with severe chronic and complex conditions and ensure the best clinical outcomes. MAXIMIZE VALUE AT LOW COST The top 5% of people with severe chronic conditions account for 50% of care spending. Practicing fragmented care doesn't deliver help in time. Oxitone generates continuous remote measurements of multiple physiological parameters and their derivatives, so any critical deviations could be flagged and notified in a timely manner. Oxitone continuous monitoring solution helps to maximize care for patients while significantly reduce cost. VitalsTone™ AI-POWERED ANALYTICS ENGINE At the core of Oxitone is the VitalsTone™ exceptionally accurate personalized data analytics engine integrated with the #1 in the market FDA/CE certified wrist medical monitor Oxitone 1000M. It passively collects and analyses multiple critical physiological parameters and their derivatives (hospital-grade) in real time and guides personalized therapeutic decision-making ULNAR BONE FlexSense™ CONTINUOUS MONITORING TECHNOLOGY Oxitone 1000M is the first FDA-cleared wrist medical monitor that works without a bulky fingertip probe. Oxitone's elastics sensors gently embrace wrist ulnar bone, do not affect local blood flow and provide superior accuracy, comfort and monitoring continuity. The technology was intensively validated through FDA clearance and numerous clinical applications. Oxitone is spotlighted on The New York Times, MobiHealthNews, MedCityNews, and Digital Health Global 100. Won awards from Cleveland Clinic, NODE.Health, Tech Tour, and Hello Tomorrow. Oxitone was a part of StartUp Health and TEDMED Hive 2014.

Pi-Cardia is a medical device company and market leader in the development of a broad portfolio of leaflet modification solutions for treating heart valves. The company has years of knowledge and expertise accumulated in degenerated valves, including calcification patterns, mode of valve failure, and impact of various methods of leaflet modification. ShortCut™ is designed to provide a safe, simple, and effective way to split leaflets of a pre-existing valve to enable TAVR in patients at risk for coronary obstruction and may assist in preserving coronary access.

We are a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Our proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. We are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. We refer to our additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T.

Premia Spine is a medical technology company based in Netanya, Israel, founded in March 2011 by Ron Sacher. The company specializes in developing innovative spinal implants aimed at improving patient outcomes. Premia Spine focuses on providing alternatives to traditional spinal fusion surgeries through minimally invasive procedures that help preserve spinal flexibility and reduce pain. The company offers a range of spinal implant systems, including the TOPS™ System, which treats spinal stenosis and spondylolisthesis while allowing for natural motion and providing pain relief. Other products include the ProMIS™ System and Nexux™ Systems, designed for treating back and leg pain through minimally invasive techniques. Premia Spine also provides training and clinical support for healthcare providers to ensure effective integration of its products into treatment protocols. With a commitment to advancing spinal care, Premia Spine has filed 20 patents and raised $7 million in funding, focusing on orthopedic and neurosurgical innovations.

Prodalim Group provides optimized solutions to bottling companies across the globe. More simply put, we do all of the hard work to get top-quality fruit juices into the hands of bottling companies, who then make sure that those same juices fill your glass. To make this happen, we start by understanding the specific needs of our customers. We proceed to carefully research the flavors consumers will like the most, meticulously choose top quality growers from whom to buy fruit, figure out the best, and most eco-friendly way to press, blend and store the juices we produce, and finally, how to effectively and efficiently transport our products to our customers, premium bottlers across the world. What's our Secret? We hold as our operational cornerstones 4 central principles that are the basis for our market beating results: Innovation Integrity and Reliability Quality Partnership and Fairness These values come to bear in the 360° solutions we offer to our customers including product research and development, sourcing of raw materials, manufacturing, blending, compounds, storing, and distribution. From our various offices and distribution centers; NL, Spain, Italy, Brazil and China, using a network of growers in 35 countries, we've constructed a wide portfolio of raw material related to the juice and citrus oils industry product offerings and organized multiple distribution centers, allowing us to be substantially more responsive and competitive to our customers. Our 350customers in over 50 countries, including some of the world's top, blue-chip bottlers are well aware of this commitment to excellence and to them. They, in turn, repay us in trust, loyalty, cooperation and close to 30 years of collaboration, and, of course, in a growing base of business activity. Prodalim brings the best solutions, in terms of product quality, efficiency, customer service and cost, to bottling companies in all corners of the planet.

Pronto Diagnostics is a leading provider of molecular diagnostic products and services, with extensive knowledge, experience and R&D capabilities in genetic analysis. ProntoLab™, Pronto's molecular services laboratory, has accreditation from the Israel Ministry of Health and ISO 9001:2008 certification. It provides both clinical diagnostics and clinical research services, which include DNA purification; sequencing and deletion/duplication analysis for any gene; fragment analysis; pharmacogenetic testing and epigenetic tests. ProntoLab™ carries out sequencing and data analysis of whole-exome, as well targeted gene panels for specific diseases and syndromes. Pronto Diagnostics has been granted exclusive distribution rights in Israel from leading international molecular diagnostic companies to high quality products and technologies. We are cooperating with the best and most advanced labs in the world such as Centogene, TheragenEtex, Sequenom, MRC-Holland, 10x Genomics, Multiplicom-Agilent, Sophia genetics, DNA Genotek and many more. Pronto Diagnostics provides highly professional technical support. Its product specialists are dedicated to supporting the company's customers wherever they may be. For more details please contact our office at : info@prontodiagnostics.com

When treating stroke, procedural time and patient safety are critical. Utilizing advanced technology backed by clinical data, Rapid Medical expands what's possible in neurovascular treatment by offering interventional devices that are fully visible and adjustable in the brain. The result? The unique ability to tailor the procedure to every patient.

RCK is an Israeli cannabis company, breeding repeatable & stable cannabis hybrid-seeds, for both medical & recreational markets.

Here at Redefine Meat, we believe the world deserves better meat – a new kind of meat that's good for the environment, kinder to animals, and of course, delicious. With cutting-edge technology, we've created plant-based ‘New Meat' that has the same flavor, texture, and versatility as animal meat. We offer a wide range of products suitable for any type of cuisine and cooking style.

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products. Previously known as BiondVax Pharmaceuticals, the company has undergone significant changes, including a shift in focus and a rebranding to reflect a new strategic direction. Scinai Immunotherapeutics is also working on an innovative plaque psoriasis treatment that has shown encouraging preclinical results.

SuperMeat is a Tel Aviv-based food tech company working to supply the world with high quality meat grown directly from animal cells. At SuperMeat, food technologists, engineers, biologists, and chefs work together to craft the world's greatest meat products, manufactured in a sustainable and animal-friendly way.

Vascular Graft Solutions (VGS), was founded in 2009 and is focusing on the development and commercialization of innovative solutions to improve the outcome of bypass surgeries. The company's leading product, the VEST (Venous External Scaffolding Technology), is a novel external mechanical support for autologous vein grafts, intended for improving vein graft longevity. Pre-clinical and clinical studies confirmed that by restraining wall tension and improving lumen uniformity, the VEST optimizes vein graft hemodynamics and mitigates vein graft disease. Randomized controlled trials and real-world data studies in Europe, demonstrated the biomechanical effect of external stenting, its statistically significant mitigation of vein graft disease, and improved clinical outcomes.

Vensica Medical is a medical device company that is designing and developing and Ultrasound catheter for the treatment of bladder cancer. Currently, after surgical removal of tumors found in the bladder, a drug is instilled into the bladder via a catheter. This treatment method is inefficient and ineffective: Urinary bladder cancer has the highest recurrence rates among all types of cancer (70%). Using Vensica's device, the drug will be instilled in a quick, pain-free procedure subsequent to the delivery of ultrasound to the urinary bladder. Ultrasound improves the uptake of the drug and its penetration into the bladder wall and is expected to improve the treatment and reduce recurrence rates.